Complications and Costs Associated with Initiation of Anti-coagulation Therapy Using Warfarin--An Observation Study  

作　　者：Jasmine Chiat Ling Ong Seng Han Lim Chai Ling Ong Liping Chen Elicia Purnata Edmund Joo Sheng See Joel Cho-Lun Chiang Vivian Shi Yin Wong Loke Khee Siow Jin Shing Hon Ming Chai Kong Chi Keong Ching 

机构地区：[1]Department of Pharmacy, Singapore General Hospital, Outram Road, Singapore 169608, Singapore [2]Department of Pharmacy, National Heart Centre Singapore, 5 Hospital Drive, Singapore 16960, Singapore [3]Department of Cardiology, National Heart Centre Singapore, 5 Hospital Drive, Singapore 169609, Singapore

出　　处：《Journal of Pharmacy and Pharmacology》2015年第6期262-267,共6页药剂与药理学（英文版）

摘　　要：To evaluate the safety and cost of anticoagulation therapy in patients newly initiated on warfarin in two institutions in Singapore. All patients newly started on warfarin between December 2011 and May 2012 were recruited and followed up for a period of 6 months. All hospitalization attributed to complications of warfarin therapy, number of INR （international normalized ratio） greater than 4 and total cost of warfarin therapy were collected and analysed. A total of 321 patients were newly initiated on warfarin for standard indications were recruited. At the end of 6 month period, 8.4% of patients were hospitalized for complication related to warfarin therapy. For patients who had stable INR while on warfarin, this rate was almost 2 times lower （3.8% vs 8.4%）. In our study group, patients started on warfarin as inpatients had higher rates of bleeding （15.1% vs 6.7%） and more 1NRs greater than 4 （0.7 per patient vs 0.11 per patient）. The cost of initating warfarin was USD660 over the first 6 months of therapy. Patients newly initiated on warfarin were at a heightened risk of bleeding complications as compared to patients already stable on warfarin therapy. This also translates to considerable costs of warfarin initiation.

关 键 词：ANTICOAGULATION WARFARIN INITIATION COMPLICATIONS cost. 

分 类 号：R9[医药卫生—药学]